Oral angiotensin-converting-enzyme inhibitors

Verme-Gibboney, Catherine

doi:10.1093/ajhp/54.23.2689

Cited by 24 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A spectrum of symptoms associated with angioedema includes well‐demarcated swelling of the tongue, lips, or face as well as edema of the mucous membranes of the mouth, throat, and nose. Involvement of the upper respiratory tract can lead to acute respiratory distress and airway obstruction, from which death may occur 16,23 . ACE inhibitor‐induced angioedema may occur more frequently than is reported due to lack of recognition of relatively mild symptoms by the patient or physician 24 or lack of documentation on the part of the physician 13,14 .…”

Section: Commentsmentioning

confidence: 99%

“…ACE inhibitor‐induced angioedema may occur more frequently than is reported due to lack of recognition of relatively mild symptoms by the patient or physician 24 or lack of documentation on the part of the physician 13,14 . An unrecognized case of angioedema may result in continued use of the ACE inhibitor and a subsequent, more severe event; it is thus imperative that patients with even mild angioedema not be restarted on ACE inhibitors 15,23 …”

Section: Commentsmentioning

confidence: 99%

“…13,14 An unrecognized case of angioedema may result in continued use of the ACE inhibitor and a subsequent, more severe event; it is thus imperative that patients with even mild angioedema not be restarted on ACE inhibitors. 15,23 Due to the nature of this "large and simple" trial, 4 additional clinical information including allergies, diet, and use of non-ALLHAT medications was not available. Physicians were urged to report all suspected cases of angioedema in their ALLHAT participants, regardless of other possible etiologies.…”

Section: Commentsmentioning

confidence: 99%

See 2 more Smart Citations

Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Piller

Ford

Davis

et al. 2006

J of Clinical Hypertension

View full text Add to dashboard Cite

Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest antihypertensive study conducted to date, randomized 42,418 participants to a diuretic (chlorthalidone), a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), or an alpha-blocker (doxazosin). Patients who developed angioedema were compared for baseline characteristics and changes in antihypertensive drug administration. Fifty-three participants developed angioedema during active follow-up: 55% were black, 60% men, and 70% were assigned to lisinopril (including 62% of black participants with angioedema), 15% to chlorthalidone, 9% to doxazosin, and 6% to amlodipine. Six percent occurred within a day of randomization and 23% within the first week. Over half did not have an increase in their assigned (blinded) antihypertensive drug before angioedema onset; 3 (6%) had a dose increase within a week before onset. One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations.

show abstract

Section: Commentsmentioning

confidence: 99%

Section: Commentsmentioning

confidence: 99%

Section: Commentsmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Piller

Ford

Davis

et al. 2006

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…Nonsteroidal anti-inflammatory drugs, which inhibit prostaglandin synthesis, reduce GFR by blocking the effect of renal vasodilatory prostaglandins in hypoperfused states 33 . Angiotensin-convertingenzyme inhibitors may induce prerenal AKI by reducing the production of angiotensin II, which maintains glomerular capillary hydrostatic pressure by constricting the glomerular efferent arterioles 34 . Cyclosporin A and other immunosuppressive drugs, such as tacrolimus and sirolimus, also cause vasoconstriction of the afferent arterioles which reduces renal perfusion, thus decreasing GFR and inducing AKI 35 .…”

Section: Drug-induced Akimentioning

confidence: 99%

The Meaning of Acute Kidney Injury and Its Relevance to Intensive Care and Anaesthesia

Moore

Bellomo

Nichol

2012

Anaesth Intensive Care

133

View full text Add to dashboard Cite

Acute kidney injury (AKI) is the new consensus term for acute renal failure. The term describes a continuum of kidney injury, a common condition in the critically ill and after major surgery, which is associated with increased mortality. The incidence of AKI in intensive care unit patients in Australia is >30% and sepsis is a major contributory factor. However, there is limited knowledge about its incidence after major surgery, except for cardiac surgery. The creation of staged AKI classification systems (RIFLE [Risk, Injury, Failure, Loss, Endstage], Acute Kidney Injury Network and the new Kidney Disease: Improving Global Outcomes criteria) has accelerated progress in critical care nephrology research by showing that even small changes in serum creatinine are associated with increased risk of death and that this risk increases progressively with severity of AKI. Recent thought and research has cast doubt over previously accepted pathophysiological views of AKI. Moreover, terms such as 'prerenal azotaemia' and 'acute tubular necrosis' are now being challenged as lacking validity, having little supportive evidence and carrying limited clinical utility. In this review, we explore the limitations of animal and human models of AKI and the implications of recent research on our current understanding of the pathophysiology of AKI. In addition, we describe conventional and novel diagnostic methods and therapies, and explore the clinical implications of the effect of fluid administration and perioperative management. Finally, we identify priorities for clinical investigations and future directions in AKI research.

show abstract

“…Rajini). [2]. However, some of the currently used ACE inhibitors have certain limitations like susceptibility to proteolytic degradation leading to side effects such as brochospasm and dry cough [3].…”

Section: Introductionmentioning

confidence: 99%

Angiotensin converting enzyme inhibitory activity of amino acid esters of carbohydrates

Kamath

Rajini

Lohith

et al. 2006

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Oral angiotensin-converting-enzyme inhibitors

Cited by 24 publications

References 0 publications

Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

The Meaning of Acute Kidney Injury and Its Relevance to Intensive Care and Anaesthesia

Angiotensin converting enzyme inhibitory activity of amino acid esters of carbohydrates

Contact Info

Product

Resources

About